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Abstract. Aim: We investigated the possibility of BMI-1 and
MEL-18 to predict survival in patients with pulmonary
squamous cell carcinoma. Materials and Methods: One
hundred and ninety-nine patients underwent surgery in our
Institute between 1995 and 2005. We used immuno -
histochemical (IHC) analysis to determine the expressions of
BMI-1 and MEL-18 and compared them with clinico -
pathological factors and survival. Results: Forty-one of 199
cases (21%) were BMI-1-positive. No correlation was found
between BMI-1 and MEL-18 expression by IHC and
clinicopathological factors. Five-year overall survival in the
BMI-1-positive group (66.8%), but not MEL-18, was
significantly better than that in the negative group (45.5%,
p=0.04). In multivariate analysis, positive BMI-1 was a
better prognostic factor of overall survival (hazard ratio
(HR)=0.561, 95% confidence interval (CI)=0.271-1.16,
p=0.12). Conclusion: BMI-1 expression, but not MEL-18, is
associated with a favorable prognosis and is a possible
prognostic factor of pulmonary squamous cell carcinoma.
Lung cancer is the major cause of malignancy-related death
worldwide (1). Approximately, 85% of lung cancer is non-
small cell lung cancer (NSCLC) and the most frequently
diagnosed histologies are adenocarcinoma and squamous cell
carcinoma. Although adenocarcinoma is becoming more
well-characterized, driver mutations of epidermal growth
factor receptor (EGFR) (2) or translocation of echinoderm
microtubule-associated protein-like 4 (EML4)-anaplastic
lymphoma kinase (ALK) (3) are known and characterized,
yet squamous cell carcinoma, the second most frequent
histology, is not well-studied. Although several molecularly
targeted therapies have been developed, the benefits of these
drugs may contribute to patients with adenocarcinoma but
not squamous cell carcinoma. The mechanisms that underlie
the carcinogenesis of squamous cell lung cancer are still
poorly understood and should be clarified to develop new
therapeutic approaches.
Polycomb group (PcG) proteins (discovered in Drosophila
as epigenetic gene silencers) are conserved gene silencers
playing a crucial role in the development of vertebrate
organisms (4). These proteins regulate cell proliferation,
senescence and tumorigenesis via well-known growth
regulatory pathways. There is increasing evidence that PcG
proteins play an important role in cancer development and
recurrence (5). PcG proteins are subdivided into two
multimeric protein complexes, that is, the polycomb
repressive complex 1 (PRC1) and the polycomb repressive
complex 2 (PRC2). The PRC1 complex includes B cell-
specific Moloney murine leukemia virus integration site 1
(BMI-1), MEL-18, MPH1/RAE28, M33 and SCMH1 (4-6).
BMI-1 is known as a key molecule in repressing p16Ink4a
and p19Arf, which are encoded by INK4A, for induction of
cell growth arrest, senescence and apoptosis. Overexpression
of BMI-1 has been found in several human malignancies,
such as breast cancer, gastric cancer, colorectal cancer,
nasopharyngeal carcinoma, melanoma, oral cancer and
bladder cancer, as a poor prognostic factor (6-13).
In addition to BMI-1, mammalian cells express a BMI-1-
related PcG protein, MEL-18, also known as polycomb
group ring finger 2 (PCGF2) (14). BMI-1 and MEL-18, both
belonging to the PRC1 complex, exhibit structurally high
homology to each other. MEL-18, a BMI-1-related PcG
protein, negatively regulates BMI-1 expression and its
expression negatively correlates with BMI-1 in proliferating
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and senescing human fibroblasts (15). Overexpression of
MEL-18 leads to repression of BMI-1 and reduction of the
transformed phenotype in malignant breast cancer cells.
Furthermore, the repression of BMI-1 is accompanied by the
reduction of Akt/protein kinase B (PKB) activity in breast
cancer cells. MEL-18 and BMI-1 may regulate the Akt
pathway in breast cancer cells, while MEL-18 functions as a
tumor suppressor by repressing the expression of BMI-1 and,
consequently, down-regulating Akt activity (15, 16).
In this study, we evaluated the association of BMI-1 and
MEL-18 expression with clinicopathological factors and
prognostic possibility in patients with stage I to III squamous
cell lung carcinoma.
Materials and Methods
Patients and samples. Clinicopathological characteristics of 199
patients with lung squamous cell carcinoma were investigated.
Patients diagnosed as stage I to III primary lung squamous cell
carcinoma had been surgically resected at the Department of
General Thoracic, Breast and Pediatric Surgery, Fukuoka University
School of Medicine and Hospital, Fukuoka, Japan, from January 1,
1995 to December 31, 2005. Our Institutional ethical committee
approved the retrospective study and waived the need for patient
consent.
We reviewed each patient’s medical records for clinical
information, including follow-up status and outcome information.
Clinicopathological parameters were evaluated, including age,
gender, smoking index (the number of cigarettes smoked per day
multiplied by the number of years of smoking), tumor size, lymph
node (LN) metastasis and adjuvant therapy. The pathological stage
was determined according to the tumor/node/metastasis (TNM)
classification of malignant tumors (Union for International Cancer
Control (UICC)).
Immunohistochemical analysis. BMI-1 and MEL-18 were detected
in paraffin sections of lung squamous carcinoma tissue. All slides
were interpreted by two independent observers in a blinded fashion.
For evaluation reliability, two independent assessors estimated the
staining positivity of two serial sections. Four micrometer sections
were prepared for tissue slides. Antigen retrieval was performed at
121˚C for 15 min in an autoclave with citrate buffer (pH 9.0) after
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Table Ⅰ. Patients’ characteristics. 
Characteristics                 All patients       BMI-1-positive        BMI-1-negative        p-Value      MEL-18-positive       MEL-18-negative         p-Value
Gender
   Male                                    181                         40                              141                     0.13                     44                               137                       0.57
   Female                                 18                           1                                17                                                   3                                 15                            
Age (Years)
   <65                                       48                           7                                41                       0.31                     12                                36                         0.79
   ≥65                                      151                         34                              117                                                 35                               116                           
Smoking index
   <400                                     38                           9                                29                       0.48                      9                                 29                         0.83
   ≥400                                    129                         23                              106                                                 29                               100                           
   Unknown                             32                           9                                23                                                   9                                 23                            
pT
   1                                           45                          10                               35                       0.49                     12                                33                         0.39
   2                                           88                          21                               67                                                  22                                66                            
   3                                           38                           7                                31                                                   5                                 33                            
   4                                           28                           3                                25                                                   8                                 20                            
pN
   0                                          128                         24                              104                      0.7                      31                                97                         0.98
   1                                           23                           5                                18                                                   5                                 18                            
   2                                           40                          11                               29                                                   9                                 31                            
   3                                            5                            1                                 4                                                     1                                  4                             
   Unknown                              3                            0                                 3                                                     1                                  2                             
Stage
   1a                                          36                           7                                29                       0.79                      9                                 27                         0.81
   1b                                         45                          10                               35                                                  12                                33                            
   2a                                          30                           7                                23                                                   5                                 25                            
   2b                                         25                           3                                22                                                   4                                 21                            
   3a                                          48                          12                               36                                                  13                                35                            
   3b                                         15                           2                                13                                                   4                                 11                            
Adjuvant therapy
   (–)                                        178                         34                              144                     0.15                     41                               137                       0.59
   (+)                                        21                           7                                14                                                   6                                 15                            
Total                                        199                         41                              158                                                 47                               152                           
deparaffinization. DAKO blocking solution (DAKO, Glostrup,
Denmark) was used to block non-specific binding. For BMI-1,
staining with anti-BMI-1 clone F6 (Millipore, MA, USA) with
diluents, 1:300, was performed overnight at 4˚C. After reaction with
3% hydrogen peroxide for 15 minutes at room temperature, RealTM
Envision HRP Rabbit/Mouse antibody (DAKO) for BMI-1 was
applied and incubated for 30 min at room temperature. For MEL-
18, staining with MEL-18 (H-115) (Santa Cruz Biotechnology, CA,
USA) with diluents, 1:100, was performed overnight at 4˚C. After
reaction with 3% hydrogen peroxide for 15 min at room
temperature, Real™ Envision HRP Rabbit/Mouse antibody (DAKO)
for MEL-18 was applied and incubated for 30 min at room
temperature.
Negative controls were incubated without the primary antibody.
IHC staining was evaluated as previously described (17).
Statistical analysis. All statistical analyses were performed using
SPSS 14.0 (SPSS Japan Inc., Tokyo, Japan). The different variables
of the tumors and normal tissues were analyzed with chi-square
tests or Fisher’s exact tests. Disease-free and overall survival were
analyzed using the Kaplan-Meier method and evaluated by the log-
rank test. Significant differences were accepted at p<0.05. 
Results
Relationship between clinicopathological characteristics, BMI-
1 and MEL-18 expression. The correlation between the
clinicopathological characteristics of pulmonary squamous cell
carcinoma and BMI-1 and MEL-18 expression was
investigated. A total of 41 of the 199 cases (21%) were BMI-
1-positive. As shown in Table I, no significant correlations
between BMI-1 expression and clinicopathological factors
were found. The expression pattern of BMI-1 is shown in
Figure 1. BMI-1-positive cases showed strong granular staining
in the nuclei of pulmonary squamous cell carcinoma from the
resected specimens, although normal bronchial cells did not
show any positive staining of BMI-1. MEL-18 was also stained
in the nuclei of pulmonary squamous cell carcinoma specimens
(positive: 47 of 199, 23.6%; Figure 2). However, normal
bronchial epithelium was not stained. MEL-18 was related with
neither clinicopathological factors nor BMI-1 expression.
Prognostic values of BMI-1 and MEL-18. The possibility of
using these proteins to predict the survival of pulmonary
squamous cell carcinoma was then examined. Figure 3
shows disease-free, disease-specific and overall survival
according to the stratification of BMI-1 expression. The
median follow-up period was 63 months. Five-year disease-
free survival in the BMI-1-positive group was better than in
the negative group (78.4% and 63.8%, respectively, p=0.045;
Figure 3A). However, five-year disease-specific survival
showed a trend of better survival in the BMI-1-positive
group (positive 71.2%, negative 57.4%, p=0.08; Figure 3B).
Five-year overall survival, including other causes of death,
showed significant difference between the two groups
(positive 66.8%, negative 45.5%, p=0.04; Figure 3C). On the
other hand, MEL-18 showed prognostic significance in
neither disease-free, nor disease-specific, nor overall survival
(p=0.15, p=0.54 and p=0.59, respectively; Figures 4A-C).
We found that smoking index, nodal involvement and BMI-
1 expression showed prognostic significance by univariate
analysis in overall survival (Table II); however, only the
smoking index, T factor and nodal involvement showed
significant prognostic value by multivariate Cox regression
analysis. BMI-1 expression showed a potential for prognostic
impact by multivariate analysis (Table II). Multivariate
analysis in disease-free survival showed that T factor and
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Table Ⅱ. Cox regression models for overall survival.
                                        Univariate analysis        Multivariate analysis
Characteristics             HR      95%CI    p-Value  HR     95%CI  p-Value
Age 70< vs. <70         0.91    0.61-1.36     0.64    1.07  0.63-1.79   0.81
Smoking index 
400> vs. 400<             2.66    1.08-6.56    0.034   5.49  1.33-22.7   0.02
T factor 
T1 vs. T2-4                  1.32    0.82-2.12     0.26    1.84   1.03-3.3   0.039
Node status 
N0 vs. N1-2                 2.02     1.34-3.1     0.001    1.8   1.01-3.19  0.045
Adjuvant 
With vs. without          1.19    0.64-2.24     0.58    0.98  0.46-2.12   0.97
BMI-1- 
positive vs. negative   0.55    0.31-0.97     0.04    0.56  0.27-1.16   0.12
MEL-18- 
positive vs. negative   0.87    0.53-1.43     0.59    0.85   0.45-1.6    0.85
HR, Hazard ratio; CI, confidence interval.
Table Ⅲ. Cox regression models for disease-free survival.
                                                               Multivariate analysis
Characteristics                            HR                 95%CI               p-Value
Age 
70< vs. <70                                0.71               0.38-1.3                 0.27
Smoking index 
400> vs. 400<                            0.97               0.4-2.33                 0.94
T factor 
T1 vs. T2-4                                 0.48              0.27-0.87               0.015
Node status 
N0 vs. N1-2                                2.11              1.16-3.84               0.014
BMI-1- 
positive vs. negative                  0.97               0.5-1.88                 0.93
MEL-18- 
positive vs. negative                  1.27              0.66-2.47                0.47
HR, Hazard ratio; CI, confidence interval.
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Figure 1. Representative BMI-1 protein expression in pulmonary squamous cell carcinoma by immunohistochemistry (IHC). Nuclei of cancer cells
were stained strongly in 3+ cases (200×, A), 2+ (B) and 1+ (C). Negative staining of pulmonary squamous cell carcinoma (D). 
Figure 2. Representative MEL-18 protein expression in pulmonary squamous cell carcinoma by immunohistochemistry (IHC). Nuclei of cancer cells
were stained strongly in 3+ cases (200×, A), 2+ (B) and 1+ (C). Negative staining of pulmonary squamous cell carcinoma (D). 
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Figure 4. Disease-free survival (A), disease-specific survival (B), and
overall survival (C) according to MEL-18 protein expression. Five-year
disease-free survival was 53.6% in the MEL-18-positive group and
71.2% in the negative group (p=0.15). Five-year disease-specific
survival was 59.9% in the MEL-18-positive group and 60.9% in
negative group (p=0.54). Five-year overall survival was 54.2% in the
MEL-18-positive group and 47.9% in the negative group (p=0.59).
Figure 3. Disease-free survival (A), disease-specific survival (B) and
overall survival (C) according to BMI-1 protein expression. Five-year
disease-free survival was 78.4% in the BMI-1-positive group and 63.8%
in negative group (p=0.045). Five-year disease-specific survival was
71.2% in the BMI-1-positive group and 57.4% in the negative group
(p=0.08). Five-year overall survival was 66.8% in BMI-1-positive group
and 45.5% in thenegative group (p=0.04). 
nodal status were significant prognostic factors; BMI-1 and
MEL-18 were not (Table III).
Discussion
BMI-1 is one of the proteins that is a member of the
polycomb group family and has a potentially critical role for
tumor progression (5). BMI-1 is known as an oncogene that
has a critical role associated with C-MYC in B-cell lymphoma
cells (15). Most studies have shown that overexpression of
BMI-1 is associated with poor prognosis in many human
cancers, including cervical, breast, lung, esophageal, stomach
and colon (6-9, 16, 18, 19). However, the opposite result, that
BMI-1 may be a favorable prognostic factor in breast cancer,
was also reported (20). It has been shown that BMI-1 is
significantly correlated with negative axillary node metastasis
and estrogen receptor (ER) status; furthermore, prognosis in
BMI-1-positive cases is significantly more favorable than in
negative cases. The suggested reason was that comparable
methods of IHC for expression levels of BMI-1 were
different in the evaluation process, including distribution and
intensity of positive cells between the two studies. Saeki et
al. reported that BMI-1 mRNA expression was inversely
correlated with nodal involvement and staging in breast
cancer. These results suggested that BMI-1 may cause
carcinogenesis in early events, but not late stage progression,
but this remains controversial. Another study of BMI-1
expression in lung cancer showed significant correlation with
early and decline in late stages of disease, which is negatively
correlated with nodal involvement (18). They reported that
silencing of BMI-1 expression induced invasiveness and
metastasis in human lung cancer cell lines in vitro. These
results support our results that the staging of lung squamous
cell cancer was not correlated with BMI-1 expression. It has
also been reported that BMI-1 repression induces epithelial-
mesenchymal transition and progression of lung cancer in
vitro. In our study, overall survival in lung squamous cell
carcinoma was inversely correlated with BMI-1 expression,
and these results were supported by a previous report (18). In
another report, BMI-1 mRNA expression in early stage breast
cancer was higher than in late stage and was inversely related
with lymph node metastasis (21). Taken together, BMI-1
expression may play a crucial role in carcinogenesis but not
progression in lung cancer. 
In this study, we focused on the expression of BMI-1 in
squamous cell carcinoma but not adenocarcinoma. The
prognostic value of BMI-1 was evaluated and positive BMI-
1 expression was a favorable prognostic factor in squamous
cell lung cancer. Multivariate analysis showed that smoking
index, T factor and nodal status were of significant value for
overall survival but the value of BMI-1 was weak. These
well-known confounding factors affected prognosis in our
study; however, BMI-1 may be a weak independent
prognostic factor. Furthermore, disease-free survival was
associated with BMI-1 expression but weakly related with
disease-specific survival. The reason why this discrepancy
between overall and disease-specific survival existed remains
unclear. A possible reason is that other causes of death, such
as pneumonia because of a high prevalence of smoking,
affected the analysis. Most studies about BMI-1 in lung
cancer were estimated in adenocarcinoma or non-small cell
carcinoma (22-24). The function of BMI-1 in pulmonary
squamous cell carcinoma may be different from in
adenocarcinoma of the lung. Although there are several driver
mutations, such as EGFR of lung adenocarcinoma, squamous
cell carcinoma of the lung is neither well-known nor
characterized. BMI-1 may be one of the critical functions for
carcinogenesis and should be studied in a larger population.
MEL-18, which was inversely expressed with BMI-1, was
evaluated in our study. However, no correlation with any
clinicopathological factors was shown and it did not have
any prognostic value in this study. MEL-18 is a regulator of
cell proliferation and quittance by BMI-1 suppression acting
as a tumor suppressor gene or oncogene (15). The reason
why our study showed no correlation between the two
proteins is unknown.
The limitations of this study are that it involves
retrospective analysis and is a single-Institution study.
Another limitation is the relatively small number of patients
used to observe differences in survival between the two
groups. Longer follow-up and an increased number of
patients in both groups may lead to further confirmation of
the results.
In conclusion, BMI-1 protein was expressed in pulmonary
squamous cell carcinoma and may be a possible prognostic
marker. Further studies should be undertaken to clarify this
hypothesis. 
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